Last updated: August 14, 2026
Sulfacetamide sodium is a mature, off-patent prescription anti-infective with limited direct financial disclosure and low barriers to generic competition. Its U.S. market is fragmented across ophthalmic solutions, dermatology creams, lotions, suspensions, cleansers, and sulfur combinations. Commercial performance depends more on manufacturer participation, pharmacy reimbursement, product availability, and dermatology prescribing patterns than on patent protection.
No public company reports standalone sulfacetamide sodium revenue. The drug is generally included within broader generic dermatology, ophthalmology, or hospital-product portfolios. The base-case outlook is stable-to-declining pricing, intermittent supply volatility, and limited opportunity for premium growth except in differentiated formulations or under-served dosage forms.
What is sulfacetamide sodium used for?
Sulfacetamide sodium is a sulfonamide antibacterial used in prescription ophthalmic and dermatologic products.
Key dosage forms and indications
| Dosage form |
Typical strength |
Principal use |
| Ophthalmic solution |
10% |
Bacterial conjunctivitis and other susceptible ocular infections |
| Ophthalmic ointment |
10% |
Ocular bacterial infections |
| Topical lotion, cream, or suspension |
10% |
Acne vulgaris and seborrheic dermatitis |
| Sulfur combination products |
Sulfacetamide sodium 10% with sulfur 5% |
Acne and rosacea-related dermatologic conditions |
| Cleansers and washes |
Usually 9.8% to 10% sulfacetamide sodium, sometimes with sulfur |
Acne, rosacea, and seborrheic dermatitis |
The drug inhibits bacterial folic-acid synthesis by competing with para-aminobenzoic acid. It is used primarily for localized treatment and has been displaced in many settings by newer topical antibiotics, azelaic acid, metronidazole, ivermectin, retinoids, and broader-spectrum ophthalmic antibiotics.
How large is the sulfacetamide sodium market?
The market is a small, mature generic segment rather than a separately tracked branded pharmaceutical market.
Public financial filings from major generic manufacturers do not normally identify sulfacetamide sodium sales. The product is bundled into categories such as topical dermatology, ophthalmology, or generic prescription medicines. Market-research estimates can differ materially depending on whether they include:
- Ophthalmic products only;
- Dermatology products only;
- Sulfur combination products;
- Hospital and institutional sales;
- Compounded preparations;
- Veterinary products;
- Global sales or U.S. sales.
The U.S. market has several commercial characteristics:
- Generic competition limits sustainable price increases.
- Product-level revenue is dispersed among multiple ANDA holders and contract manufacturers.
- Dermatology products can command higher prices when packaged as cleansers, foams, or branded generics.
- Ophthalmic products are more exposed to supply-chain constraints and sterile manufacturing requirements.
- Sulfur combination products can retain higher reimbursement than plain sulfacetamide sodium because of formulation differentiation and fewer directly substitutable products.
Public claims databases and prescription-audit vendors may report prescription volume and sales estimates, but those figures are not equivalent to audited manufacturer revenue. No reliable public source establishes a consolidated global sulfacetamide sodium market value.
What is the financial trajectory for sulfacetamide sodium?
The financial trajectory is best characterized as mature, low-growth, and price-sensitive.
Revenue drivers
Sulfacetamide sodium revenue is affected by:
- Number of active manufacturers;
- ANDA approvals and product discontinuations;
- Pharmacy benefit-manager reimbursement;
- Dermatology prescribing volume;
- Availability of sulfur combination products;
- Ophthalmic sterile-filling capacity;
- Insurance coverage and prior authorization;
- Wholesale acquisition price and generic reimbursement;
- Substitution with newer topical or ophthalmic therapies.
Plain sulfacetamide sodium products have limited pricing power. The strongest commercial positions are more likely to arise from a differentiated delivery system, an established dermatology brand, or reliable supply rather than from the active ingredient itself.
Financial outlook by segment
| Segment |
Growth outlook |
Margin outlook |
Main commercial risk |
| Plain ophthalmic solution |
Flat to declining |
Low to moderate |
Generic price compression and sterile supply disruption |
| Topical sulfacetamide sodium |
Flat |
Low |
Substitution by newer dermatology products |
| Sulfacetamide sodium/sulfur products |
Stable niche |
Moderate relative to plain products |
Reimbursement pressure and formulation competition |
| Branded generic cleansers |
Stable to modest growth in selected niches |
Higher than commodity products |
Brand erosion and payer restrictions |
| Compounded products |
Limited formal market visibility |
Variable |
Regulatory and quality-control constraints |
The most probable long-term scenario is erosion in unit price offset partly by stable prescription demand and occasional supply shortages. A material revenue expansion would require a new indication, a premium delivery system, an acquisition of a differentiated dermatology brand, or a regulatory event reducing competition.
When did sulfacetamide sodium lose exclusivity?
Sulfacetamide sodium is an old sulfonamide active ingredient with no meaningful remaining composition-of-matter exclusivity in the U.S. Its commercial products are generally approved through abbreviated new drug applications or legacy regulatory pathways.
The commercial exclusivity profile is:
| Protection type |
Current position |
| Composition-of-matter patent |
Expired or not commercially relevant |
| Original product patent |
Expired |
| New chemical entity exclusivity |
Not applicable to current generic products |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not a current market protection |
| Formulation patents |
Product-specific and generally limited |
| Method-of-use patents |
Limited practical impact |
| Regulatory exclusivity |
No broad market exclusivity identified |
| Biosimilar exclusivity |
Not applicable |
The absence of meaningful exclusivity allows multiple manufacturers to compete for the same prescriptions. Product-level patents could theoretically protect a particular vehicle, combination, or delivery system, but those rights would not block plain sulfacetamide sodium products.
What patents protect sulfacetamide sodium products?
No active foundational patent is required to market ordinary sulfacetamide sodium ophthalmic or topical products. The active ingredient has been available for decades, and generic versions do not depend on a current ingredient patent.
Formulation patents
Potentially protectable subject matter includes:
- A specific emulsion or suspension;
- A low-irritation topical vehicle;
- A preservative system;
- A cleanser or foam composition;
- A stabilized ophthalmic formulation;
- A particular sulfacetamide sodium and sulfur ratio;
- Packaging that improves stability or dosing;
- A delivery device or metered applicator.
These rights would protect the specific formulation, not sulfacetamide sodium as a molecule. Their commercial value depends on whether competing products can design around the claims and whether physicians, pharmacies, or payers treat the formulation as substitutable.
Method-of-use patents
Method-of-use protection could cover a defined dermatologic condition, dosing regimen, patient population, or combination treatment. Such patents have limited value for an old generic active ingredient because:
- Physicians can prescribe alternative products;
- Generic manufacturers can seek approval with different labeling;
- Enforcement can be difficult when treatment occurs through physician-directed prescribing;
- The underlying active ingredient remains broadly available.
The FDA Orange Book is the principal source for patents listed against approved drug products. Sulfacetamide sodium products generally do not have a patent estate comparable to newer branded dermatology or ophthalmology drugs. FDA, Orange Book, and approved-label records should be reviewed at the individual product level because listing status can vary by formulation and sponsor.[1]
What is the FDA regulatory status of sulfacetamide sodium?
Sulfacetamide sodium is an FDA-regulated prescription drug active ingredient used in approved ophthalmic and topical products.
FDA-approved product categories include sulfacetamide sodium ophthalmic solutions and topical products for dermatologic indications. Labeling commonly includes contraindications for sulfonamide hypersensitivity and warnings relating to severe skin reactions, local irritation, and secondary overgrowth of nonsusceptible organisms.[2]
The regulatory profile has four business implications:
- The active ingredient has a long safety and clinical-use history.
- New entrants can generally pursue an ANDA where the reference product and dosage form are appropriate.
- Sterile ophthalmic products face higher manufacturing and quality requirements than nonsterile topical products.
- Dermatology products may require careful bioequivalence and vehicle characterization, particularly where the formulation affects delivery.
The FDA Drugs@FDA database and DailyMed identify approved labeling, sponsors, dosage forms, strengths, and product status.[2,3]
What is the Orange Book status of sulfacetamide sodium?
Sulfacetamide sodium does not have a single Orange Book status because the database lists individual approved products rather than the active ingredient as one unified commercial asset.
For most generic products, the relevant status is:
- Approved prescription product;
- ANDA-based approval;
- No active ingredient patent blocking ordinary generic entry;
- Product-specific listing and marketing status;
- Potential discontinuation or inactive status depending on the sponsor.
An Orange Book review should distinguish among:
- Ophthalmic solution;
- Ophthalmic ointment;
- Topical lotion or cream;
- Sulfacetamide sodium and sulfur combinations;
- Products approved under different reference standards.
A listed product may remain approved while being commercially discontinued. That distinction matters for market sizing, supply analysis, and acquisition valuation.[1]
Which companies manufacture sulfacetamide sodium?
Manufacturing is fragmented. Products have been marketed by generic pharmaceutical companies, dermatology-focused companies, contract manufacturers, and legacy branded-generic sponsors.
Historically marketed or approved products have included sulfacetamide sodium products associated with companies such as:
- Akorn;
- Bausch Health and legacy dermatology businesses;
- Taro Pharmaceutical Industries;
- Perrigo and affiliated generic operations;
- Teva Pharmaceutical Industries;
- Fougera Pharmaceuticals;
- Hi-Tech Pharmaceuticals;
- Other ANDA holders and contract manufacturers.
The active manufacturer roster changes as companies discontinue low-volume products, transfer ANDAs, or outsource production. A manufacturer may hold an approval without actively supplying all channels.
Manufacturing barriers
The principal barriers are operational rather than intellectual-property based.
For ophthalmic products, relevant barriers include:
- Sterile filling;
- Preservative control;
- Container-closure integrity;
- Microbial limits;
- Stability testing;
- FDA inspection compliance;
- Reliable access to ophthalmic packaging.
For topical products, barriers are lower but still include:
- Consistent particle size and suspension characteristics;
- Vehicle reproducibility;
- Skin-tolerance testing;
- Preservative performance;
- Scale-up validation;
- Tube, pump, or cleanser packaging.
These requirements can create short-term supply advantages for manufacturers with reliable facilities, even when long-term patent protection is absent.
Which companies are challenging sulfacetamide sodium exclusivity?
No meaningful current Paragraph IV campaign is associated with sulfacetamide sodium as a core branded product. The active ingredient is already broadly generic, and ordinary products generally lack a patent barrier that would justify a major patent challenge.
Paragraph IV litigation is more relevant to:
- A branded sulfacetamide sodium and sulfur product with listed formulation patents;
- A new delivery system;
- A proprietary dermatology combination;
- A branded product with an Orange Book-listed method-of-use or formulation patent.
For ordinary sulfacetamide sodium ophthalmic solution or topical products, competition is more likely to arise through ANDA filing, product approval, manufacturing entry, and commercial contracting than through patent litigation.
What patent litigation and settlement agreements affect sulfacetamide sodium?
Publicly visible market activity does not show a major current patent-litigation or settlement framework governing ordinary sulfacetamide sodium products.
The principal legal risks are instead:
- Product-liability claims;
- Manufacturing-quality investigations;
- False advertising or labeling disputes;
- ANDA-related disputes involving a particular branded formulation;
- Contract and supply disagreements;
- State substitution and reimbursement disputes.
Any settlement involving a sulfacetamide sodium product would need to be evaluated against the specific branded reference product, listed patent claims, ANDA certification, and agreed launch date. There is no broad settlement date controlling generic sulfacetamide sodium entry across the market.
How does sulfacetamide sodium compare with competing drugs?
Dermatology competition
| Product |
Common use |
Competitive position |
| Sulfacetamide sodium |
Acne, seborrheic dermatitis, rosacea-related treatment |
Low-cost, established, niche |
| Azelaic acid |
Acne and rosacea |
Strong clinical and commercial substitute |
| Metronidazole |
Rosacea |
Established alternative |
| Ivermectin |
Rosacea |
Branded and generic competition |
| Doxycycline |
Moderate inflammatory acne and rosacea |
Systemic alternative |
| Benzoyl peroxide |
Acne |
Broad OTC and prescription competition |
| Topical retinoids |
Acne |
Standard first-line competition |
| Clindamycin |
Acne |
Common topical alternative, often combined with benzoyl peroxide |
Sulfacetamide sodium and sulfur combinations may remain relevant when clinicians seek a non-retinoid topical option or when patients cannot tolerate other products. Their use is constrained by sulfonamide allergy concerns, odor or cosmetic acceptability, irritation, and payer policies.
Ophthalmic competition
| Product category |
Examples |
Competitive pressure |
| Broad-spectrum fluoroquinolones |
Moxifloxacin, ofloxacin |
High |
| Aminoglycoside combinations |
Tobramycin, gentamicin combinations |
Moderate to high |
| Macrolides |
Erythromycin ophthalmic products |
Moderate |
| Polymyxin combinations |
Trimethoprim/polymyxin B |
High |
| Sulfonamide products |
Sulfacetamide sodium ophthalmic solution |
Niche and declining |
Sulfacetamide sodium remains inexpensive but is less attractive when clinicians prefer broader-spectrum coverage, lower dosing frequency, or more contemporary guideline positioning.
What generic entry risks exist for sulfacetamide sodium?
Generic-entry risk is already realized for plain sulfacetamide sodium products. The relevant commercial question is whether additional entrants will cause further price erosion or disrupt supply.
Generic launch scenarios
| Scenario |
Market effect |
| One additional ophthalmic entrant |
Moderate price pressure; possible share loss for smaller suppliers |
| Multiple entrants |
Significant reimbursement and wholesale-price compression |
| Manufacturer exit |
Temporary shortage risk and higher spot pricing |
| New sulfur combination |
Share shift from incumbent branded generic products |
| Premium vehicle launch |
Limited volume but higher revenue per prescription |
| Contract manufacturing failure |
Channel-specific stockouts and substitution |
A new generic entrant would need to secure FDA approval, qualified manufacturing capacity, pharmacy distribution, and payer acceptance. Approval alone would not guarantee meaningful market share because the market is low value and pharmacy networks often favor established suppliers.
What is the geographic coverage of sulfacetamide sodium?
The United States has the clearest public regulatory record through FDA databases. Sulfacetamide sodium products are also marketed internationally, but availability varies by country, formulation, and prescription rules.
Geographic commercial differences include:
- U.S. products are generally prescription medicines;
- European availability is more dependent on national marketing authorizations;
- Some countries have limited dermatology use because of sulfonamide-allergy concerns or preference for alternatives;
- Emerging markets may rely on locally manufactured topical products;
- Ophthalmic sterile products face higher country-specific manufacturing and registration requirements.
Global revenue is difficult to aggregate because the same active ingredient may be sold under different names, strengths, combinations, and regulatory classifications.
How strong is the sulfacetamide sodium patent estate?
The patent estate is weak for the active ingredient and ordinary dosage forms.
Patent-strength assessment
| Attribute |
Assessment |
| Molecule protection |
None of practical commercial significance |
| Blocking patent risk |
Low for plain products |
| Formulation protection |
Possible but narrow |
| Method-of-use protection |
Limited |
| Design-around risk |
High |
| Litigation leverage |
Low |
| Generic substitution risk |
High |
| Manufacturing moat |
Moderate for sterile ophthalmic products |
| Brand value |
Higher for recognized dermatology products |
The strongest defensible positions are operational, regulatory, and commercial. A company with dependable sterile manufacturing, established dermatology distribution, or a differentiated vehicle may outperform a nominally equivalent competitor despite having no meaningful ingredient patent.
Key Takeaways
- Sulfacetamide sodium is a mature generic active ingredient with no meaningful remaining composition-of-matter exclusivity.
- The market spans ophthalmic, topical, and sulfur combination products.
- No public company reports standalone sulfacetamide sodium revenue.
- Financial performance is driven by volume, reimbursement, manufacturer participation, and product availability.
- Plain products face persistent generic price pressure.
- Sulfur combinations and differentiated dermatology vehicles have better margin potential.
- Ophthalmic manufacturing creates more operational barriers than topical production.
- No major current Paragraph IV or patent-settlement framework governs ordinary sulfacetamide sodium products.
- The principal competitive threats are azelaic acid, metronidazole, ivermectin, benzoyl peroxide, retinoids, clindamycin, and broad-spectrum ophthalmic antibiotics.
- The most plausible commercial upside lies in formulation differentiation, reliable supply, and focused dermatology distribution rather than new patent protection for the active ingredient.
FAQs
Is sulfacetamide sodium still commercially attractive for generic manufacturers?
Only selectively. It can be attractive when a manufacturer has existing ophthalmic capacity, a dermatology sales channel, or an opportunity to acquire a discontinued or under-supplied product. Commodity entry without a distribution advantage is less attractive.
Does sulfacetamide sodium have biosimilar competition?
No. Sulfacetamide sodium is a small-molecule drug, so competition occurs through generic-drug pathways rather than FDA biosimilar approval.
Can a new formulation of sulfacetamide sodium receive patent protection?
Yes. A novel vehicle, stabilized composition, delivery system, or specific combination could qualify for patent protection if it meets applicable novelty, nonobviousness, and disclosure requirements. That patent would protect the formulation, not the underlying active ingredient.
Are sulfacetamide sodium and sulfur products interchangeable with plain sulfacetamide sodium?
Usually not automatically. The products can differ in active ingredients, dosage form, labeling, formulation, and substitution status. Pharmacy substitution depends on the applicable FDA approval and state law.
What is the main investment risk in sulfacetamide sodium?
The principal risk is low market value per prescription combined with generic price compression. Operational disruptions can produce temporary upside, but they do not create durable exclusivity.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Library of Medicine. (2024). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2024). Approved drug product labels and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers
